# Soligenix, Inc.: financial statements, quarterly

SNGX · Nasdaq · CIK 812796 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sngx.md) · [Financials](/companies/sngx/financials.md) · [Filings](/companies/sngx/filings.md) · [Insiders](/companies/sngx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sngx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [130](/filings/0001558370-24-015054.md) | [245 d](/filings/0001558370-25-003459.md) | [117](/filings/0001558370-25-007171.md) | [2.3](/filings/0001558370-25-011554.md) | [0.0 d](/filings/0001104659-25-108475.md) | [0.0 d](/filings/0001104659-26-037701.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $k | [110](/filings/0001558370-24-015054.md) | [222 d](/filings/0001558370-25-003459.md) | [117](/filings/0001558370-25-007171.md) | [2.3](/filings/0001558370-25-011554.md) | [0.0 d](/filings/0001104659-25-108475.md) | [0.0 d](/filings/0001104659-26-037701.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $k | [20.0](/filings/0001558370-24-015054.md) | [23.3 d](/filings/0001558370-25-003459.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [826](/filings/0001558370-24-015054.md) | [778 d](/filings/0001558370-25-003459.md) | [1,095](/filings/0001558370-25-007171.md) | [501](/filings/0001558370-25-011554.md) | [969](/filings/0001104659-25-108475.md) | [2,659 d](/filings/0001104659-26-037701.md) | [1,942](/filings/0001104659-26-057904.md) | [1,677](/filings/0001104659-26-092681.md) | [1,584](/filings/0001104659-25-108475.md) | [2,283 d](/filings/0001104659-26-037701.md) | [1,782](/filings/0001104659-26-057904.md) | [974](/filings/0001104659-26-092681.md) |
| Operating income | $k | [(1,779)](/filings/0001558370-24-015054.md) | [(2,138) d](/filings/0001558370-25-003459.md) | [(2,117)](/filings/0001558370-25-007171.md) | [(1,745)](/filings/0001558370-25-011554.md) | [(1,865)](/filings/0001104659-25-108475.md) | [(3,712) d](/filings/0001104659-26-037701.md) | [(3,027)](/filings/0001104659-26-057904.md) | [(2,764)](/filings/0001104659-26-092681.md) | [(2,580)](/filings/0001104659-25-108475.md) | [(3,475) d](/filings/0001104659-26-037701.md) | [(2,885)](/filings/0001104659-26-057904.md) | [(2,099)](/filings/0001104659-26-092681.md) |
| Income tax | $k | [0.0 d](/filings/0001558370-24-015054.md) | [(607) d](/filings/0001558370-25-003459.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(1,663)](/filings/0001558370-24-015054.md) | [(1,820) d](/filings/0001558370-25-003459.md) | [(1,915)](/filings/0001558370-25-007171.md) | [(1,645)](/filings/0001558370-25-011554.md) | [(1,719)](/filings/0001104659-25-108475.md) | [(2,987) d](/filings/0001104659-26-037701.md) | [(2,951)](/filings/0001104659-26-057904.md) | [(2,702)](/filings/0001104659-26-092681.md) | [(2,531)](/filings/0001104659-25-108475.md) | [(2,896) d](/filings/0001104659-26-037701.md) | [(2,825)](/filings/0001104659-26-057904.md) | [(1,987)](/filings/0001104659-26-092681.md) |
| Diluted EPS | $ per share | [(2.56)](/filings/0001558370-24-015054.md) | not reported | [(2.91)](/filings/0001558370-25-007171.md) | [(1.31)](/filings/0001558370-25-011554.md) | [(0.78)](/filings/0001104659-25-108475.md) | not reported | [(0.97)](/filings/0001104659-26-057904.md) | [(0.82)](/filings/0001104659-26-092681.md) | [(0.58)](/filings/0001104659-25-108475.md) | not reported | [(0.28)](/filings/0001104659-26-057904.md) | [(0.12)](/filings/0001104659-26-092681.md) |
| Basic EPS | $ per share | [(2.56)](/filings/0001558370-24-015054.md) | not reported | [(2.91)](/filings/0001558370-25-007171.md) | [(1.31)](/filings/0001558370-25-011554.md) | [(0.78)](/filings/0001104659-25-108475.md) | not reported | [(0.97)](/filings/0001104659-26-057904.md) | [(0.82)](/filings/0001104659-26-092681.md) | [(0.58)](/filings/0001104659-25-108475.md) | not reported | [(0.28)](/filings/0001104659-26-057904.md) | [(0.12)](/filings/0001104659-26-092681.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $m | [11.0](/filings/0001558370-23-018818.md) | [9.5](/filings/0001558370-25-003459.md) | [7.8](/filings/0001558370-24-007782.md) | [9.7](/filings/0001558370-24-011740.md) | [10.3](/filings/0001558370-24-015054.md) | [8.8](/filings/0001104659-26-037701.md) | [7.6](/filings/0001558370-25-007171.md) | [5.3](/filings/0001558370-25-011554.md) | [10.9](/filings/0001104659-25-108475.md) | [8.8](/filings/0001104659-26-092681.md) | [6.6](/filings/0001104659-26-057904.md) | [10.2](/filings/0001104659-26-092681.md) |
| Total assets | $m | [11.3](/filings/0001558370-23-018818.md) | [9.8](/filings/0001558370-25-003459.md) | [8.1](/filings/0001558370-25-007171.md) | [9.9](/filings/0001558370-25-011554.md) | [10.5](/filings/0001104659-25-108475.md) | [9.0](/filings/0001104659-26-037701.md) | [7.7](/filings/0001104659-26-057904.md) | [5.8](/filings/0001104659-26-092681.md) | [11.3](/filings/0001104659-25-108475.md) | [9.2](/filings/0001104659-26-092681.md) | [6.9](/filings/0001104659-26-057904.md) | [10.5](/filings/0001104659-26-092681.md) |
| Current liabilities | $m | [5.5](/filings/0001558370-23-018818.md) | [6.2](/filings/0001558370-25-003459.md) | [7.2](/filings/0001558370-24-007782.md) | [6.4](/filings/0001558370-24-011740.md) | [4.5](/filings/0001558370-24-015054.md) | [4.8](/filings/0001104659-26-037701.md) | not reported | [3.6](/filings/0001558370-25-011554.md) | [3.4](/filings/0001104659-25-108475.md) | [3.7](/filings/0001104659-26-092681.md) | [3.6](/filings/0001104659-26-057904.md) | [3.7](/filings/0001104659-26-092681.md) |
| Total liabilities | $m | [7.1](/filings/0001558370-23-018818.md) | [7.3](/filings/0001558370-25-003459.md) | [7.3](/filings/0001558370-24-007782.md) | [6.4](/filings/0001558370-24-011740.md) | [4.5](/filings/0001558370-24-015054.md) | [4.8](/filings/0001104659-26-037701.md) | [3.8](/filings/0001558370-25-011554.md) | [3.9](/filings/0001558370-25-011554.md) | [3.7](/filings/0001104659-25-108475.md) | [3.9](/filings/0001104659-26-092681.md) | [3.8](/filings/0001104659-26-057904.md) | [3.9](/filings/0001104659-26-092681.md) |
| Long-term debt | $m | [1.4](/filings/0001558370-23-018818.md) | [1.0](/filings/0001558370-25-003459.md) | not reported | not reported | not reported | [0.0](/filings/0001558370-25-003459.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [4.2](/filings/0001558370-24-015054.md) | [2.5](/filings/0001104659-26-037701.md) | [0.8](/filings/0001558370-25-011554.md) | [3.5](/filings/0001104659-25-108475.md) | [5.9](/filings/0001104659-25-108475.md) | [4.1](/filings/0001104659-26-092681.md) | [3.9](/filings/0001104659-26-092681.md) | [1.8](/filings/0001104659-26-092681.md) | [7.6](/filings/0001104659-25-108475.md) | [5.3](/filings/0001104659-26-092681.md) | [3.1](/filings/0001104659-26-092681.md) | [6.6](/filings/0001104659-26-092681.md) |

- Cash and equivalents: not reported
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,686) d](/filings/0001558370-24-015054.md) | [(1,828) d](/filings/0001558370-25-003459.md) | [(1,342)](/filings/0001558370-25-007171.md) | [(1,918) d](/filings/0001558370-25-011554.md) | [(2,910) d](/filings/0001104659-25-108475.md) | [(2,233) d](/filings/0001104659-26-037701.md) | [(1,847)](/filings/0001104659-26-057904.md) | [(2,742) d](/filings/0001104659-26-092681.md) | [(2,933) d](/filings/0001104659-25-108475.md) | [(2,745) d](/filings/0001104659-26-037701.md) | [(2,358)](/filings/0001104659-26-057904.md) | [(1,707) d](/filings/0001104659-26-092681.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.6 d](/filings/0001104659-25-108475.md) | [2.0 d](/filings/0001104659-26-037701.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2.9](/filings/0001558370-23-018818.md) | [2.9](/filings/0001558370-24-007782.md) | [0.5](/filings/0001558370-24-011740.md) | [0.6](/filings/0001558370-24-015054.md) | [0.7](/filings/0001558370-25-007171.md) | [1.3](/filings/0001558370-25-011554.md) | [2.2](/filings/0001104659-25-108475.md) | [3.0](/filings/0001104659-26-057904.md) | [3.3](/filings/0001104659-26-092681.md) | [4.3](/filings/0001104659-25-108475.md) | [10.2](/filings/0001104659-26-057904.md) | [16.0](/filings/0001104659-26-092681.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 21,765,479 at 2026-07-31, from the cover of the [10-Q filed 2026-08-07](/filings/0001104659-26-092681.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.